3 Promising Penny Stocks With Market Caps Up To $300M

As the U.S. market faces a challenging period with indices like the S&P 500 and Nasdaq experiencing significant declines, investors are becoming increasingly cautious about where to allocate their resources. In such times, penny stocks—often associated with smaller or newer companies—can present unique opportunities for those seeking potential growth at lower entry points. Despite their vintage-sounding name, penny stocks continue to hold relevance in today's market by offering a mix of affordability and potential for strong returns when backed by solid financials.

Top 10 Penny Stocks In The United States

Click here to see the full list of 763 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Sterling Bancorp (Southfield MI) (NasdaqCM:SBT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sterling Bancorp, Inc. (Southfield, MI) serves as the unitary thrift holding company for Sterling Bank and Trust, F.S.B., with a market capitalization of $255.22 million.

Operations: Sterling Bank and Trust, F.S.B. generates its revenue primarily from its Community Banking segment, which accounts for $66.06 million.

Market Cap: $255.22M

Sterling Bancorp's recent activities highlight its strategic shift, with the company set to delist from Nasdaq following the sale of its banking unit to EverBank for US$261 million. This move comes amid declining earnings, with net income dropping to US$1.16 million in Q4 2024 from US$5.06 million a year earlier. Despite having a stable loans-to-deposits ratio and sufficient allowance for bad loans, Sterling's profit margins have decreased significantly, and return on equity remains low at 0.6%. The experienced board and management team face challenges as they navigate this transitional phase.

• Dive into the specifics of Sterling Bancorp (Southfield MI) here with our thorough balance sheet health report.
• Learn about Sterling Bancorp (Southfield MI)'s historical performance here.

Prelude Therapeutics (NasdaqGS:PRLD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel precision cancer medicines for underserved patients, with a market cap of $44.11 million.

Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $7 million.

Market Cap: $44.11M

Prelude Therapeutics faces significant challenges as it navigates its current financial and operational landscape. The company, with a market cap of US$44.11 million, is pre-revenue despite reporting US$7 million in sales from its biotechnology segment. It recently received a Nasdaq bid price notice due to non-compliance with the minimum bid price requirement, risking potential delisting if not resolved by September 2025. Prelude's cash runway extends for over a year without debt concerns, but it remains unprofitable with increasing losses and negative return on equity at -96.74%. Management is experienced; however, volatility persists in share prices amidst strategic refocus on SMARCA2 degrader development programs.

• Click here to discover the nuances of Prelude Therapeutics with our detailed analytical financial health report.
• Examine Prelude Therapeutics' earnings growth report to understand how analysts expect it to perform.

Cato (NYSE:CATO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: The Cato Corporation, with a market cap of $73.37 million, operates as a specialty retailer focusing on fashion apparel and accessories primarily in the southeastern United States.

Operations: The company's revenue is primarily generated from the United States, totaling $649.81 million.

Market Cap: $73.37M

Cato Corporation, with a market cap of US$73.37 million, operates under financial pressure as it remains unprofitable with increasing losses over the past five years at a rate of 15.2% per year. Despite stable weekly volatility and seasoned management and board members, Cato's revenue for the full year fell to US$649.81 million from US$708.06 million a year ago, while net loss improved slightly to US$18.06 million from US$23.94 million previously reported. The company is debt-free with short-term assets covering both short- and long-term liabilities, but negative return on equity remains a concern for investors in penny stocks.

• Navigate through the intricacies of Cato with our comprehensive balance sheet health report here.
• Gain insights into Cato's historical outcomes by reviewing our past performance report.

Seize The Opportunity

• Dive into all 763 of the US Penny Stocks we have identified here.
• Interested In Other Possibilities? These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com